NASDAQ:OCUL

Ocular Therapeutix Stock Insider Trading

Healthcare > Biotechnology

Buy OCUL

*Your capital is at risk

$8.35

+0.0400 (+0.481%)

At Close: Jun 03, 2026

Ocular Therapeutix Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 45.47. In total, the insiders bought 9.66M and sold 1.84M OCUL shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	45.47
● Buy	9.66M shares
● Sell	1.84M shares
55% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Feb 12, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 45.47. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 28, 2026 Buy	Common Stock G-Gift	Dugel Pravin See Remarks	Officer	394 696 Value: $3.61M
May 28, 2026 Sell	Common Stock G-Gift	Dugel Pravin See Remarks	Officer	394 696 Value: $0
May 26, 2026 Sell	Common Stock S-Sale	Nayak Sanjay Chief Strategy Officer	Officer	1 858 Value: $15.2K
May 26, 2026 Sell	Common Stock S-Sale	Kaiser Peter Chief Development Officer	Officer	2 967 Value: $24.3K
May 26, 2026 Sell	Common Stock S-Sale	Dugel Pravin See Remarks	Officer	21 156 Value: $173.5K
May 26, 2026 Sell	Common Stock S-Sale	Heier Jeffrey S. Chief Scientific Officer	Officer	3 018 Value: $24.7K
Apr 09, 2026 Buy	Common Stock G-Gift	Dugel Pravin See Remarks	Officer	394 696 Value: $3.67M
Apr 09, 2026 Sell	Common Stock G-Gift	Dugel Pravin See Remarks	Officer	394 696 Value: $0
Feb 23, 2026 Sell	Common Stock S-Sale	Nayak Sanjay Chief Strategy Officer	Officer	1 759 Value: $14.6K
Feb 23, 2026 Sell	Common Stock S-Sale	Heier Jeffrey S. Chief Scientific Officer	Officer	3 057 Value: $25.3K
Feb 23, 2026 Sell	Common Stock S-Sale	Dugel Pravin See Remarks	Officer	20 056 Value: $166.1K
Feb 23, 2026 Sell	Common Stock S-Sale	Kaiser Peter Chief Development Officer	Officer	2 810 Value: $23.3K
Feb 20, 2026 Buy	Common Stock P-Purchase	Lindstrom Richard L Md Director	Director	60 229 Value: $461.4K
Feb 20, 2026 Sell	Common Stock S-Sale	Waheed Nadia Chief Medical Officer	Officer	3 510 Value: $27.2K
Feb 12, 2026 Sell	Common Stock S-Sale	Dugel Pravin See Remarks	Officer	124 882 Value: $1.13M
Feb 12, 2026 Sell	Common Stock S-Sale	Nayak Sanjay Chief Strategy Officer	Officer	10 348 Value: $93.5K
Feb 12, 2026 Sell	Common Stock S-Sale	Notman Donald Chief Operating Officer	C-Suite Officer	11 446 Value: $103.5K
Feb 12, 2026 Sell	Common Stock S-Sale	Waheed Nadia Chief Medical Officer	Officer	7 863 Value: $71.1K
Feb 04, 2026 Sell	Common Stock S-Sale	Notman Donald Chief Operating Officer	C-Suite Officer	6 035 Value: $51.5K
Feb 02, 2026 Sell	Common Stock S-Sale	Notman Donald Chief Operating Officer	C-Suite Officer	5 455 Value: $49.9K
Jan 21, 2026 Buy	Common Stock A-Award	Robinson David Wayne Global Cco	Officer	136 000 Value: $1.55M
Jan 21, 2026 Buy	Stock Option (Right to Buy) A-Award	Robinson David Wayne Global Cco	Officer	416 000 Value: $4.75M
Jan 21, 2026 Buy	Common Stock J-Other	Robinson David Wayne Officer	Officer	0 Value: $0
Jan 20, 2026 Buy	Stock Option (Right to Buy)	Robins Jason Shand Interim CFO	C-Suite Officer	68 195 Value: $806.1K
Jan 20, 2026 Buy	Stock Option (Right to Buy)	Robins Jason Shand Interim CFO	C-Suite Officer	110 600 Value: $898.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT OCULAR THERAPEUTIX

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammati...

Read Full Profile Here